Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1443-1447

  Liu, Xingrong ^a,b   Smith, Bill J ^a   Chen, Cuiping ^a   Callegari, Ernesto ^a   Becker, Stacey L ^a   Chen, Xi ^a   Cianfrogna, Julie ^a   Doran, Angela C ^a   Doran, Shawn D ^a   Gibbs, John P ^a   Hosea, Natilie ^a   Liu, Jianhua ^a   Nelson, Frederick R ^a   Szewc, Mark A ^a   Van Deusen, Jeffrey ^a  

^a PFIZER INC   (United States)

^b Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CP 141938; FLUOXETINE; GLYCOPROTEIN P; METHOXY 3 [(2 PHENYL PIPERADINYL 3 AMINO) METHYL] PHENYL W METHYL METHANE SULFON AMIDE; N[3 (4' FLUOROPHENYL) 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; PROPRANOLOL; SARCOSINE; THEOBROMINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN HOMOGENATE; BRAIN LEVEL; BRAIN SLICE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG EVALUATION, PRECLINICAL; FLUOXETINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; THEOBROMINE; THEOPHYLLINE;

EID: 33747860858     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008201     Document Type: Article

References (30)

1. Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855-861.
2. Bonati M, Kanto J, and Tognoni G (1982) Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 7:312-335.
3. Carneheim S and Stahle L (1991) Microdialysis of lipophilic compounds: a methodological study. Pharmacol Toxicol 69:378.
4. Cherubin CE, Eng RH, Norrby R, Modai J, Humbert G, and Overturf G (1989) Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 11:526-548.
5. Cunningham VJ, Gunn RN, and Matthews JC (2004) Quantification in positron emission tomography for research in pharmacology and drug development. Nucl Med Commun 25:643-646.
6. de Lange EC and Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703.
7. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the Mdr1a/1b knockout mouse model. Drug Metab Dispos 33:165-174.
8. Garver DL (1989) Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels. J Clin Psychopharmacol 9:277-281.
9. Hammarlund-Udenaes M, Paalzow LK, and de Lange EC (1997) Drug equilibration across the blood-brain barrier - pharmacokinetic considerations based on the microdialysis method. Pharm Res (NY) 14:128-134.
10. Hillered L, Vespa PM, and Hovda DA (2005) Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Nutr 22:3-41.
11. Joukhadar C, Derendorf H, and Muller M (2001) Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 57:211-219.
12. Khramov AN and Stenken JA (1999) Enhanced microdialysis extraction efficiency of ibuprofen in vitro by facilitated transport with Beta-cyclodextrin. Anal Chem 71:1257-1264.
13. Kusuhara H and Sugiyama Y (2004) Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Delivery Rev 56:1741-1763.
14. Lin JH and Lu AYH (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
15. Lindberger M, Tomson T, and Stahle L (2002) Microdialysis sampling of carbamazepine, phenytoin and phenobarbital in subcutaneous extracellular fluid and subdural cerebrospinal fluid in humans: an in vitro and in vivo study of adsorption to the sampling device. Pharmacol Toxicol 91:158-165.
16. Liu X, Tu M, Kelly RS, Chen C, and Smith BJ (2004) Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 32:132-139.
17. Liu X and Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Dev 8:505-512.
18. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262.
19. Maurer TS, DeBartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
20. Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, Prange HW, Gleiter CH, and Brockmoller J (2002) Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 54:592-603.
21. Nyberg G, Axelsson R, and Martensson E (1981) Cerebrospinal fluid concentrations of thioridazine and its main metabolites in psychiatric patients, Eur J Clin Pharmacol 19:139-148.
22. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, and Stupp R (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728-3736.
23. Reiter PD and Doron MW (1996) Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. J Perinatol 16:331-335.
24. Sawchuk RJ and Elmquist WF (2000) Microdialysis in the study of drug transporters in the CNS. Adv Drug Delivery Rev 45:295-307.
25. Scheyer RD, During MJ, Hochholzer JM, Spencer DD, Cramer JA, and Mattson RH (1994a) Phenytoin concentrations in the human brain: an in vivo microdialysis study. Epilepsy Res 18:227-232.
26. Scheyer RD, During MJ, Spencer DD, Cramer JA, and Mattson RH (1994b) Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neurology 44:1469-1472.
27. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Delivery Rev 56:1825-1857.
28. Smith BJ, Doran AC, McLean S, Tingley FD 3rd, O'Neil BT, and Kajiji SM (2001) P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther 298:1252-1259.
29. Stain-Texier F, Boschi G, Sandouk P, and Scherrmann JM (1999) Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol 128:917-924.
30. Wode-Helgodt B and Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology 73:55-62.